Moolec Science Announces Effectiveness of Share Consolidation
Moolec Science (NASDAQ:MLEC) completed a 15-for-1 share consolidation, so every 15 ordinary shares of par value US$0.10 were consolidated into 1 ordinary share with par value US$1.50.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moolec Science (NASDAQ:MLEC) completed a 15-for-1 share consolidation, so every 15 ordinary shares of par value US$0.10 were consolidated into 1 ordinary share with par value US$1.50.
The company said the consolidation was consummated effective as of January 5, 2026 and that the consolidation became effective on January 5, 2025 at 8:00 a.m. Eastern Time, with market quotes reflected on a consolidation-adjusted basis at the start of trading today.
Post-consolidation, issued and outstanding shares were reduced from 10,891,761 to 726,118. Shares and publicly traded warrants continue to trade under symbols MLEC and MLECW; new CUSIP numbers are G6223S125 (shares) and G6223S117 (warrants).
Positive
- 15-for-1 consolidation completed
- Issued shares reduced from 10,891,761 to 726,118
- Trading reflected on a consolidation-adjusted basis at market open
- New share par value set at $1.50
Negative
- Outstanding share count reduced by approximately 93% (10,891,761 to 726,118)
- Consolidation may change liquidity and trading dynamics
Details
News Market Reaction – MLEC
On Jan 6, the first trading day after this news, MLEC closed 11.63% below the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Share consolidation ratio
- 15-for-1
- Reverse split effective January 5, 2026
- Pre-consolidation par value
- US$0.10
- Per ordinary share before consolidation
- Post-consolidation par value
- US$1.50
- Per ordinary share after consolidation
- Pre-consolidation shares
- 10,891,761
- Issued and outstanding before consolidation
- Post-consolidation shares
- 726,118
- Issued and outstanding after consolidation
- Effective time
- 8:00 a.m. Eastern Time
- Consolidation effectiveness on January 5, 2026
- 52-week high
- $157.05
- Pre-news 52-week high level
- 52-week low
- $3.0765
- Pre-news 52-week low level
Historical Context
-
Nasdaq letter on not meeting $2.5M stockholders’ equity requirement and non-compliance.
-
Announcement of 15-for-1 share consolidation to address Nasdaq minimum bid rule.
-
Record GLASO safflower campaign with 1,100 acres and higher yields in 2025.
-
Nasdaq letter over delayed Form 20-F and need to resolve reporting non-compliance.
-
Nasdaq notice on sub-$1.00 bid price and appeal requesting 180-day plan period.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
par value financial
cusip financial
publicly traded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 5, 2026 / Moolec Science SA ("Moolec" or the "Company") today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on December 16, 2025, and the resolutions adopted by the Company's board of directors on December 19, 2025, the Company has consummated, effective as of January 5, 2026, the previously announced share consolidation at a ratio of 15-for-1, so that all shareholders holding every 15 ordinary shares of par value of US
As a result, every 15 ordinary shares of the Company, par value US
The Share Consolidation became effective on January 5, 2025, at 8:00 a.m. Eastern Time (the "Effective Date") and is reflected in the market as of the start of trading today on a consolidation-adjusted basis.
The Company's ordinary shares continue to trade on The Nasdaq Stock Market under the symbol "MLEC" under a new CUSIP number G6223S 125. The Company's publicly traded warrants continue to trade under the symbol "MLECW" under the same CUSIP number G6223S 117.
As a result of the Share Consolidation, the number of issued and outstanding Shares was reduced from 10,891,761 to 726,118 Shares. The Share Consolidation does not otherwise affect the Company's business or operations.
Registered shareholders are not required to take any action to receive shares in connection with the Share Consolidation. Shareholders who hold their shares through a brokerage firm, bank, dealer, custodian or other nominee will have their positions automatically adjusted to reflect the Share Consolidation, subject to their broker's particular processes, and will not be required to take any action in connection therewith.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact: ir@moolecscience.com (phone: +5493412034927)
SOURCE: Moolec Science SA
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.